Jared Holza healthcare equity strategist at Mizuho, detailed that Eli Lilly is leading the pharmaceutical sectorespecially in the weight loss drugs branch, together with Novo Nordisk.
Eli Lilly’s stock performance has been more than outstanding. In the last twelve months alone, Its shares, including dividends, appreciated more than 97%; and in the last five years, 746%.
This way, The corporation’s market capitalization rose to USD 861 billionwhich allowed it to become the tenth largest in the world. And if that were not enough, Holz believes that “there is still room” so that it continues to expand.
“The one thing I come back to again and again when I look at both stocks is what the supply and demand metrics look like for the GLP-1 (diabetes and weight loss drug) market and we are still, I think, in the stages of childhood, considering that it has only been about a year since both drugs were on the market specifically for obesity”detailed the executive.
“And then we talk about all the market demand that seems limitless at this point. Plus, you have all these different catalysts, not to cure, but at least to address all these other underlying medical conditions that make the drugs even better.”he added.
In this context, Holz pointed out that it is very difficult to predict whether the king of the segment will be Eli Lilly or Novo Nordisk, but what is a fact is that Both companies are “top” in the innovative weight loss market.
“I do think the news will flow over the next 6 to 12 months and even next year will be potentially prolific because we will be talking about more and more indications that the drugs satisfy”the expert commented.
Investing in Eli Lilly from Argentina
For those interested, From Argentina you can invest in Eli Lilly quickly and easily. All you have to do is open a client account in a brokerage company regulated by the National Securities Commission such as Bull Market Brokers, a free process that will not take more than five minutes, and, after depositing the desired funds, acquire Cedears.
Cedears or Argentine Deposit Certificates are instruments that are equivalent to buying the underlying stock listed abroad (NYSE: LLY), but they can be traded in pesos (BCBA: LLY) and follow the evolution of the CCL dollar, so they allow evade the Argentine risk and, at the same time, hedge against a possible exchange rate jump.
